Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 51991-750

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 51991-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing its core bicyclic and thiophene ring system with associated functional groups including the amine hydrochloride moiety.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: placebo (dashed line) and Duloxetine delayed-release capsules (solid line), illustrating relapse rates in patients over a period up to approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph depicting the proportion of patients with relapse over time (days) from randomization for Duloxetine delayed-release capsules compared to placebo. The x-axis shows time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. The graph includes two curves, one solid line for Duloxetine delayed-release capsules and one dashed line for placebo, illustrating lower relapse proportions in the Duloxetine group over the study period.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing how patient improvement varies with increasing pain relief percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: DUL 60mg BID, DUL 60mg QD, and placebo, showing higher patient improvement percentages for DUL 60mg BID and QD compared to placebo across increasing pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph depicting percent improvement in pain from baseline plotted against the percentage of patients improved. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows increasing thresholds of pain improvement percentage from 0 to 100.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares results for Duloxetine (DUL) at doses of 120 mg, 60 mg, and 20 mg once daily, against placebo. The graph shows patient improvement trends at various pain improvement thresholds from over 0% to 100%.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF) comparing Duloxetine Delayed-Release 60/120 mg once daily and placebo. The vertical axis shows percentage of patients improved from 0 to 100%, and the horizontal axis shows percent improvement from baseline pain from 0 to 100%. Two lines represent the two groups, with Duloxetine showing consistently higher patient improvement percentages than placebo across most pain improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved by placebo and Duloxetine Hydrochloride 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. The Duloxetine 60 mg group consistently shows higher improvement percentages than placebo across the range of pain improvement levels.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two data sets: placebo and Duloxetine 60/120 mg once daily, with Duloxetine generally showing higher patient improvement percentages across pain improvement levels.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

Label for Duloxetine Delayed-Release Capsules, USP 20 mg, oral capsule form containing 90 capsules. The label states the active ingredient as duloxetine hydrochloride USP equivalent to 20 mg duloxetine per capsule. It includes storage instructions, manufacturer details showing Breckenridge Pharmaceutical, Inc., and a barcode. The label also contains a pharmacist instruction to dispense the Medication Guide and a reserved area for GTIN/batch/expiration data printing.*

FDA Label Image

Principal Display Panel (30 mg Capsule Bottle Label)

Label for Duloxetine Delayed-Release Capsules, USP 30 mg. The oral capsule contains 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine. Packaged by Breckenridge Pharmaceutical, Inc., the label indicates storage instructions at 25°C (77°F) and a package size of 90 capsules. The label includes barcode, NDC 51991-747-90, and dispensing instructions for pharmacists.*

FDA Label Image

Principal Display Panel (60 mg Capsule Bottle Label)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Breckenridge Pharmaceutical, Inc. The label states each capsule contains 67.3 mg of duloxetine hydrochloride USP equivalent to 60 mg duloxetine. The label includes storage instructions, a pharmacist warning, Rx only designation, and a quantity of 1,000 capsules. Manufactured by Towa Pharmaceutical Europe, S.L. and distributed by Breckenridge Pharmaceutical, Inc. A barcode and revision date of 06/2020 are visible.*

FDA Label Image

Principal Display Panel (40 mg Capsule Bottle Label)

Label for Duloxetine Delayed-Release Capsules, USP 40 mg by Breckenridge Pharmaceutical, Inc. The label indicates each capsule contains 44.9 mg of duloxetine hydrochloride equivalent to 40 mg duloxetine. It directs storage at 25°C (77°F) with permitted excursions between 15-30°C and contains 30 capsules. Manufacturer and distributor information is included along with dispensing instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.